Get the Stockscreener App
8.13
0.62%
0.05
After Hours:
8.12
-0.01
-0.12%
Unicycive Therapeutics Inc stock is traded at $8.13, with a volume of 715.40K.
It is up +0.62% in the last 24 hours and up +22.81% over the past month.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
See More
Previous Close:
$8.08
Open:
$8.18
24h Volume:
715.40K
Relative Volume:
1.38
Market Cap:
$217.07M
Revenue:
$675.00K
Net Income/Loss:
$-26.62M
P/E Ratio:
-5.1774
EPS:
-1.5703
Net Cash Flow:
$-31.34M
1W Performance:
+13.55%
1M Performance:
+22.81%
6M Performance:
+81.47%
1Y Performance:
+1,243%
1-Day Range:
$7.935
$8.34
1-Week Range:
$7.08
$8.344
52-Week Range:
$0.47
$8.344
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
8.13 | 215.74M | 675.00K | -26.62M | -31.34M | -1.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Unicycive Therapeutics : May 2026 Corporate Presentation - marketscreener.com
Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
B. Riley Initiates Unicycive Therapeutics at Buy With $22 Price Target - Moomoo
B. Riley Financial Begins Coverage on Unicycive Therapeutics (NASDAQ:UNCY) - MarketBeat
B. Riley Securities initiated coverage on Unicycive Therapeutics with a new price target - Quantisnow
UNCY Forecast, Price Target & Analyst Ratings | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - ChartMill
Unicycive (NASDAQ: UNCY) outlines 2026 vote, board changes and executive pay - Stock Titan
UNCY Stock Price, Quote & Chart | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - ChartMill
Unicycive Therapeutics (UNCY) Stock: Why Profit Growth (Edges Up) 2026-04-20Professional Trade Ideas - Xã Thanh Hà
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Connect - ACCESS Newswire
UNCY Options Volatility — NASDAQ:UNCY - TradingView
UNCY Options Chain — NASDAQ:UNCY - TradingView
Equities Analysts Offer Predictions for UNCY Q1 Earnings - National Today
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. t - GuruFocus
Unicycive Therapeutics to Present at Annual Healthcare Conference - National Today
Unicycive CEO to Present at Needham Conference - National Today
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm - Morningstar
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Brookline Capital Markets Estimates UNCY Q2 Earnings - MarketBeat
Market Leaders: Should you avoid Unicycive Therapeutics Inc stock right now2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
Growth Recap: What is the earnings history of Unicycive Therapeutics IncTreasury Yields & Real-Time Market Sentiment Reports - baoquankhu1.vn
Brookline Capital cuts Unicycive stock price target on share count By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
What happens to Unicycive Therapeutics (UNCY) Stock in recession | Price at $6.68, Up 0.91%Trending Buy Opportunities - Xã Châu Thành
Benchmark cuts Unicycive Therapeutics price target on updated assumptions By Investing.com - Investing.com Canada
Unicycive Therapeutics director Gaurav Aggarwal resigns from board - Investing.com UK
Unicycive Therapeutics director Gaurav Aggarwal resigns from board By Investing.com - Investing.com India
Unicycive Therapeutics, Inc. Files Form 8-K Announcing Departure and Appointment of Directors and Officers - Minichart
Unicycive Therapeutics (UNCY) director Gaurav Aggarwal steps down from board - Stock Titan
Unicycive Therapeutics | 8-K: Current report - Moomoo
Gaurav Aggarwal resigns from Unicycive Board - TradingView — Track All Markets
Unicycive Therapeutics, Inc. Announces Resignation of Gaurav Aggarwal from the Board of Directors, Effective April 6, 2026 - marketscreener.com
Benchmark Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $15.00 - MarketBeat
Is Unicycive Therapeutics (UNCY) Stock a Safe Investment | Price at $6.62, Down 4.47%Crowd Sentiment Stocks - Xã Thanh Hà
Aug Movers: Should you avoid Unicycive Therapeutics Inc stock right now2026 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
ARTV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
HC Wainwright Boosts Earnings Outlook for Unicycive Therapeutics - National Today
HC Wainwright Issues Positive Estimate for UNCY Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Guggenheim Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Unicycive Therapeutics (UNCY) Target Price Lowered by Guggenheim | UNCY Stock News - GuruFocus
Guggenheim Has Lowered Expectations for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price - MarketBeat
Noble Financial Has Positive Forecast for UNCY Q1 Earnings - MarketBeat
UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval - stocktwits.com
UNCY SEC FilingsUnicycive Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY) - The Globe and Mail
Noble Financial Brokers Boost Earnings Estimates for UNCY - MarketBeat
H.C. Wainwright reiterates Unicycive stock rating, $22 target By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Noble Financial Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):